CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device ...

Effect of an Invitation or the Effect of Participation: What Should Randomized Controlled Trials of Cancer Screening Examine? In two articles that accompany this editorial, 9,10 the potential of ...

Determining the specificity of HLA antibodies is arguably one of the most important contributions by the HLA laboratory today. For patients that have low-to-moderate levels of antibody, using a ...

Guyana will soon become the first country within the Caribbean region capable of performing Human Leukocyte Antigen (HLA) ...

A32:01 carriage is strongly associated with risk of lamotrigine-induced DRESS, according to new research being presented at the 2026 AAAAI Annual Meeting.

Greenwich LifeSciences reports preliminary HLA data from Phase III trial FLAMINGO-01 evaluating GLSI-100 for preventing breast cancer recurrences. Greenwich LifeSciences, Inc. provided an update on ...